Benjamin W Muir, Jennifer A E Payne, Jennifer H Martin, Riley O' Shea, Sarigama Rajesh, Lewis D Blackman, Hsin-Hui Shen, Chad Heazlewood, Vipul Bansal, Branwen Morgan
{"title":"An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for infections.","authors":"Benjamin W Muir, Jennifer A E Payne, Jennifer H Martin, Riley O' Shea, Sarigama Rajesh, Lewis D Blackman, Hsin-Hui Shen, Chad Heazlewood, Vipul Bansal, Branwen Morgan","doi":"10.1038/s44259-024-00070-3","DOIUrl":null,"url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.</p>","PeriodicalId":520007,"journal":{"name":"npj antimicrobials and resistance","volume":"3 1","pages":"9"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836273/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj antimicrobials and resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s44259-024-00070-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
